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Abstract
Background: Aurora kinases (Aurora-A, B and C) belong to a family of conserved serine/threonine kinases which
are key regulators of cell cycle progression. Aurora-A and Aurora-B are expressed in somatic cells and involved in
cell cycle regulation while aurora-C is meiotic chromosome passenger protein. As Aurora kinase C is rarely
expressed in normal somatic cells and has been found over expressed in many cancer lines. It is suggested that
Aurora-C-T191D is not hyperactive mutant.
Result: Aurora-C-T191D variant form was investigated and compared with wild type. The overexpression of Aurora-
C-T191D was observed that it behaves like Aurora-C wild type (aurC-WT). Both Aurora-C-T191D and aurC-WT
induce abnormal cell division resulting in centrosome amplification and multinucleation in transiently transfected
cells as well as in stable cell lines. Similarly, Aurora-C-T191D and aurC-WT formed foci of colonies when grown on
soft agar, indicating that a gain of Aurora-C activity is sufficient to transform cells. Furthermore, we reported that
NIH-3 T3 stable cell lines overexpressing Aurora-C-T191D and its wild type partner induced tumour formation when
injected into nude mice, demonstrating the oncogenic activity of enzymatically active Aurora kinase C. Interestingly
enough tumour aggressiveness was positively correlated with the rate of kinase activity, making Aurora-C a
potential anti-cancer therapeutic target.
Conclusion: These findings proved that Aurora C-T191D is not hyperactive but is constitutively active mutant.
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Background
Aurora kinases are a conserved family of serine/threo-
nine kinases that are pivotal to the successful execution
of cell division. Three Aurora kinases (Aurora-A, -B,
and -C), which share sequence homology in their central
catalytic kinase domains, have been identified in mam-
mals [1]. All the three mammalian Aurora kinases are
implicated as mitotic regulators and due to their ele-
vated expression profiles detected in many human can-
cers, have generated significant interest in the cancer
research field.
Aurora-C is predominantly expressed in the testis
[2,3] and is mainly restricted to meiotically dividing
spermatocytes [4] and mouse oocytes [5]. Aurora-C is
also associated with inner centromere protein (INCENP)
in male spermatocytes. Moreover, it is reported that
overexpressed Aurora-C kinase behaves like a dominant
negative kinase for Aurora-B leading to a cytokinesis
defect [6]. Aurora-C disrupts the chromosome passenger
protein complexes necessary for cytokinesis. Aurora-C
can fulfil the role of Aurora-B in centromere assembly,
kinetochore- microtubule attachment, the spindle
assembly checkpoint and cytokinesis and, thus, possibly,
Aurora-C regulates mitosis by the same mechanisms as
Aurora-B in those somatic tissues in which it is overex-
pressed. Additional potential roles for Aurora-C in
somatic tissues could include cooperative or modulating
functions in mitosis, or non-mitotic functions such as
gene regulation via phosphorylation of histone H3 [7].
Overexpression of Aurora-C in cancerous tissues and
cell lines also raises questions about its potential role in
carcinogenesis and its effect on the proliferative capacity
of tumour cells [8,9]. The expression levels of Aurora-C,
Aurora-B and Aurora-B splice variants are commonly
altered in tumour cell lines and tissues [10-13]. These
alterations in expression have been associated with
* Correspondence: sanaullahkust@gmail.com
3Department of Zoology, Kohat University of Science and Technology, Kohat,
Pakistan
Full list of author information is available at the end of the article
Khan et al. BMC Cell Biology 2012, 13:8
http://www.biomedcentral.com/1471-2121/13/8
© 2012 Khan et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.tumourigenesis, tumour metastasis and tumour aggres-
sion. Aurora kinase inhibition by small molecules has
been intensively studied recently as a possible cancer
therapy [10,14-18].
It is reported that Aurora-C-T191D is hyperactive
mutant and its relative activity is sevenfold higher than
the activity of Aurora-C-WT [19]. But we report that
Aurora-C-T191D is not hyperactive but is constitutively
active and behaves exactly like its partner Aurora C-
WT.
Methods
Construction of vectors
Human aurora-C cDNA was obtained from pET21b-
aurora-C [6] by BglII/EcoRI digestion and inserted into
pEGFP-C3 plasmid (Clonetech USA). Green fluores-
cence protein (GFP) -aurC-WT DNA was used as a
template to obtain K72R, expressing kinase dead GFP-
tagged aurC and GFP-aurC-T191D, expressing the con-
stitutively active GFP-tagged aurC by double PCR site
directed mutagenesis (Quick change site-directed muta-
genesis kit, Stratagene USA), following manufacturer’s
instructions. The GFP-alone empty vector pEGFP-C3
was used as a control.
Cell line and transfection
Mouse NIH-3 T3 cells were used in all experiments.
Cells were grown in Dulbecco’s Modified-Eagle Medium
(DMEM) (Gibco USA) containing 10% Fetal Bovine
Serum- (PAA France) and 1% Penstrep (GIBCO- 10000
units/ml penicillin + 10000 units/ml streptomycin).
Cells were transfected in Lipofectamine™ 2000 transfec-
tion reagents (Invitrogen USA) with GFP-aurC-WT,
GFP-aurC-CA, GFP-aurC-KD and GFP-alone plasmid
DNA, following manufacturer’s instructions. For estab-
lishment of stable cell line, 800 μg/ml Geneticin G-418
(PAA France) was added in culture media, changing the
media twice a week. Clonal selection was performed
after 14 days, keeping the cells under continuous pres-
sure of Geneticin G-418.
Kinase assay
Equal number of stable Cells of GFP-aurC-WT, GFP-
aurC-CA, GFP-aurC-KD and GFP-alone were lysed in
L-buffer (1% NP40, 250 mM NaCl, 5 mM EDTA, 50
mM NaF, 20 mM Tris-HCl pH 7.5, 1 mM AEBSF, 0.2%
Okadaic Acid, Protease inhibitor cocktail (Roche Ger-
many) and 1 mM Na3VO4). Cell lysates were sonicated
and incubated on ice for twenty minutes. The lysates
were centrifuged at 13000 rpm for 15 minutes and
supernatants were pre-cleared with protein G-sepharose
beads (GE Healthcare USA) for twenty minutes at 4°C.
The pre-cleared lysates were incubated with 5 μgo f
Anti-GFP antibody (Roche) and protein G-sepharose
beads for two hours at 4°C. The lysates were again cen-
trifuged at 13000 rpm for five minutes at 4°C and the
pellets were washed three times with L-buffer containing
500 mM NaCl. The pellets were resuspended in L-buffer
and divided into three aliquots, one for kinase assay, on
aliquot for western blotting and the third aliquot was
saved as a backup at -20°C. The aliquots to be used for
kinase assay were washed three times with kinase buffer
(50 mM Tris-HCl, pH 7.5, 25 mM NaCl, 10 mM
MgCl2, 0.1% Triton).
The pellets were resuspended in 20 μl of kinase buffer
containing additional 1 mM DTT, 10 μMA T P ,5μCi
g32P ATP 3000 Ci/mmol (Amersham Pharmacia Bio-
tech USA) and 4 μg of histone H3 (Millipore 14-494
USA). The reaction mix was incubated at 30°C for 30
minutes. Proteins were then separated on 12.5% SDS-
polyacrylamide gel electrophoresis. The gel was stained
with coomassie blue, dried and analysed by a phosphori-
mager (Molecular Dynamics USA).
Soft agar assay
Nine clones each of GFP-aurC-WT and GFP-aurC-CA,
and four clones each of GFP-aurC-KD and GFP-alone
were tested with this in vitro transformation assay.
10,000 cells/well in a 6-well plate in triplicate were
g r o w ni n2m lt o pa g a rc o n t a i n i n g2 XD M E Mm e d i a ,
20% fetal bovine serum and 1% agarose. Geneticin-G-
418 was added 24 hours after seeding. Media were chan-
ged twice a week. Thirty days after seeding, well plates
were stained with 0.005% crystal violet dye and the
numbers of colonies were counted.
Immunofluorescence
10
5 cells were grown on 12 mm glass cover slips in a
12-well plate. Cells were washed with PBS and fixed
with cold methanol for 10 minutes at -20°C. Fixed cells
were washed three times with TBS and then saturated
with 1%BSA + 0.1%Tween20 prepared in PBS for 1
hour at room temperature. Primary antibodies in 1%
BSA + 0.1%Tween20 in PBS were added on the cells
(mouse anti-gamma tubulin, GTU-88-T6557, 1:2500
(Sigma USA); rabbit anti-phospho histone H3 ser-10-
06570, 1:1000 (Millipore USA), rabbit anti-GFP- 632375,
1: 2000 (Clonetech USA) for 2 hours at 4°C, on slow
agitation and then washed three times for 10 minutes
with TBS. The cells were then incubated with secondary
antibodies (anti-mouse Alexa-555, 1: 1000; anti-rabbit
Alexa-555, 1:1000; anti-rabbit Alexa-488, 1:1000 (Invi-
trogen USA) for 1 hour at room temperature on slow
agitation, protected from light, washed again with TBS,
three times for 10 minutes and then mounted with
mounting media- Prolong-Gold (Invitrogen USA), con-
taining DNA staining dye, DAPI. Images were collected
using Leica DMRXA2 fluorescent microscope with 63×
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objective. Photographs were taken using a black and
white cool snap ES camera (Roper Scientific Canada)
and images were processed using Metamorph Software
(Universal Imaging USA). A minimum of 600 cells was
counted for each condition.
Western blotting
Cells were lysed in RIPA buffer (1% NP40, 50 mMTris
HCl, pH 7.5, 150 mM NaCl, 0.25% Sodium deoxycholate,
2 mM EGTA, Protease Inhibitor cocktail (Roche USA).
Cell lysates were sonicated and cleared by centrifugation
at 13000 rpm for 20 minutes. Proteins were quantified by
Bradford method (BioRad USA). Cell lysates were boiled
for 5 minutes at 95°C in Laemmli sample buffer. Equal
amounts of protein samples were loaded onto 10% SDS-
PAGE gel for electrophoresis and then transferred onto
nitrocellulose membrane. Membranes were blocked with
5% milk-TBST for 1 hour at room temperature and incu-
bated overnight at 4°C with primary antibodies {Mouse
anti-GFP, 1:1000, (Sigma USA); Rabbit polyclonal anti-
a u r C ,1 : 2 5 0 ,( Z y m e dU S A ) } .M e m b r a n e sw e r ew a s h e d
three times for 10 minutes each with TBST and then incu-
bated for 1 hour at room temperature with secondary anti-
bodies {(Anti-mouse coupled with HRP, 1:5000; Anti-
rabbit coupled with HRP, 1:30000, (Jackson USA)}. Mem-
branes were washed again with TBST as stated above and
then revelation was done with chemiluminiscent, Pico or
Dura (Pierce USA).
Tumour growth
Female nude mice of 3 weeks age, housed in microisola-
tor units under controlled humidity and temperature
were fed with sterile diet and water. Stable cell clones to
be injected were stained overnight with DilC18(3)
(FluoProbes USA) prior to injection. Seven million cells
of each were injected subcutaneously in the abdominal
region of each mouse. Each mouse was injected with
two different clones, one on each side of the abdomen.
Tumour sizes were monitored every 10 days by direct
observation and the day of sacrifice, using Kodak image
station 2000 (Kodak USA) by an excitation of 535 nm
that detected cells stained with DilC18(3). Images were
then analysed, using Kodak Molecular Imaging Software.
Tumour volumes were then determined according to
t h ef o r m u l a ,L×W×H×π/6, shown in mm. Mice
were sacrificed when the tumour size reached 1-2 mm
3
or two months after injection. Tumours were removed,
put immediately in liquid nitrogen and then stored at
-80°C for further analysis.
Immunohistochemistry
Ten-micrometer thick frozen sections of tumours or
remaining injected cells were cut on a cryostat (Leica,
Milton Keynes, UK) and mounted onto uncoated glass
slides. Classical Feulgen staining or Hemalin counter-
staining were performed. Immunohistochemistry was
performed with rabbit monoclonal KI-67 (1.200, Epi-
tomics, clone SP6) and anti-phospho histone- H3 ser-10
(Millipore USA) and anti-HRP (Jackson USA) secondary
antibodies.
Statistical analysis
Non-parametric Mann-Whitney test was performed and
the results were considered statistically significant for a
p-value under 0.05.
Results
Establishment of GFP-aurC stable cell lines
NIH-3 T3 cells were transiently transfected with GFP-
aurC-WT (Wild type), GFP-aurC-CA (constitutively
active) and GFP-alone. The expression of GFP-aurC
protein was controlled by western blotting 24 hours
after transfection with two different antibodies, anti-GFP
and anti-aurC (Figure 1A, B). GFP-aurC was identified
in GFP-aurC-WT, GFP-aurC-CA and GFP-aurC-KD at
65 KDa with anti-GFP and anti-aurC antibodies. This
band is not present in GFP-alone samples. However, we
identified GFP-alone at 29 KDa only with anti-GFP-
alone antibody.
Stable cell lines were generated for GFP-aurC-WT,
GFP-aurC-CA and GFP-alone. The level of expression
of GFP-aurC and GFP-alone proteins was checked in all
stable cell clones with anti-GFP antibody (Figure 1C-F).
The level of expression was varied from clone to clone.
Overexpressed GFP-aurC-WT and GFP-aurC-CA are active
kinases
Kinase activity of GFP-aurC was controlled in vitro,
GFP-aurC-WT, GFP-aurC-CA, GFP-aurC-KD and GFP-
alone proteins were immunoprecipitated with anti-GFP
antibody and histone-H3-ser10 was used as a substrate.
Both the GFP-aurC-WT and GFP-aurC-CA showed
kinase activity but the GFP-alone did not show any
kinase activity (Figure 1G). We also checked the kinase
activity of GFP-aurC-WT, GFP-aurC-CA and GFP-alone
in vivo in stable cell lines and the phosphorylation of
Histone H3 was assayed. The number of positive cells
for Histone H3-serine-10 phosphorylated was found
almost two fold higher in GFP-aurC-WT and GFP-
aurC-CA compared to GFP-alone (Figure 1H, I). Four
clones were assayed for each condition.
Overexpression of active GFP-aurC results in abnormal
centrosome number and polyploidy
We used g-tubulin staining, a centrosomal marker to
assess abnormal centrosome amplification (more than
two centrosomes per cell) and DNA staining (DAPI) to
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It was found that the percentage of cells with abnormal
centrosome amplification in GFP-aurC-WT and GFP-
aurC-CA was almost 5 times higher than GFP-alone in
transiently transfected NIH-3 T3 cells (Figure 2A, B, E,
F). Same ratio between GFP-aurC-WT and GFP-aurC-
Figure 1 Western blots, showing GFP-aurC and GFP-alone proteins after 24 hours of transient transfection with GFP-alone, GFP-aurC-
KD GFP-aurC-CA and GFP-aurC-WT plasmid DNA with mouse Anti-GFP antibody (A) and with rabbit Anti-aurC antibody (B). Western
blots showing the level of expression of GFP-aurC protein in three stable clones of GFP-aurC-KD (KD1 to KD3), four stable clones of GFP-aurC-CA
(CA1 to CA4), three stable clones each of GFP-aurC-WT (WT1 to WT3) and GFP-alone (GFP1 to GFP3) illustrating the different level of expression
of GFP-aurC and GFP proteins by different clones. The antibody used was mouse anti-GFP (C& D) and anti-b tubulin antibody as a loading
control (E&F ); (G) Kinase assay GFP-aurC-WT, GFP-aurC-CA and GFP-alone clones, using histone-H3 as a substrate. (H 1,2,3,4) The left column
shows DAPI stained cells and the right column shows phosphorylated cells with Histone-H3 ser-10. (H-1) GFP-aurC-WT and (H-2) GFP-aurC-CA
(H-3) GFP-aurC-KD. (H-4) GFP-alone (I) Histogram shows the percentage of cells with phosphorylation on histone H3 of GFP-aurC-WT, GFP-aurC-
CA, GFP-aurC-KD and GFP-alone.
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lines. For multinucleation, we found that the percentage
of multinucleated cells in GFP-aurC-WT and GFP-
aurC-CA was 5 times higher than multinucleated cells
in GFP-alone in transiently transfected NIH-3 T3 cells.
Same difference in GFP-aurC-WT and GFP-aurC-CA
Figure 2 Abnormal centrosome amplification and multinucleation. The immunoflorescent microscopy images (A-G) show abnormal
centrosome amplification and multinucleation observed in GFP-aurC-WT, GFP-aurC-CA with negative control GFP-alone. (A&B) more than two
centrosomes/cell appeared as white dots with anti-g tubulin staining in GFP-aurC-CA and GFP-aurC-WT respectively. (C) and (D) show
multinucleation (more than one nucleus/cell in GFP-aurC-CA and GFP-aurC-WT respectively. (E) Two centrosomes per cell and only one nucleus/
cell in G2 phase of GFP-aur-KD. (F) histogram showing the percentage of cells with more than 2 centrosomes/cell of 96 hours after transient
transfection in GFP-aurC-CA, GFP-aurC-WT and GFP-alone cells. (G) histogram shows the percentages of multinucleated cells of 96 hours after
transient transfection in GFP-aurC-CA, GFP-aurC-WT and GFP-alone.
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showing a clear difference between the two populations
i.e. GFP-aurC-WT + GFP-aurC-CA and GFP-aurC-KD
+ GFP-alone (Figure 2C, D, E, G). It was showed that
overexpression of active GFP-aurC results in both
abnormal centrosome amplification and multinucleation.
Aurora kinase C and in vitro transformation
The ability of GFP-aurC was assessed to transform cells
in soft agar assay with GFP-aurC-WT and GFP-aurC-
CA, and GFP-alone NIH-3 T3 stable cell clones. Nine
clones each of GFP-aurC-WT and GFP-aurC-CA and
four clones of GFP-alone were tested for growth on soft
agar (Figure 3A, B). All the clones of GFP-aurC-WT &
GFP-aurC-CA formed a large number of foci of colo-
nies. In contrast, stable cell clones of GFP-alone formed
negligible number of small colonies. The data showed
that only active overexpressed GFP-aurC has the poten-
tial to transform NIH-3 T3 cells.
Aurora kinase C and in vivo transformation
To test whether NIH-3 T3 cells overexpressing GFP-
aurC were able to induce neoplastic transformation in
vivo, eight clones each of GFP-aurC-WT and GFP-
aurC-CA and four clones each of GFP-alone were
injected (seven million cells of each clone) subcuta-
neously in Swiss nu/nu mice. Tumours sizes were moni-
tored every 10 days after injection by both direct and
indirect measurements. The direct method used was
measurements by vernier calliper and the indirectly
through fluorometry in live mice. Cells stained with
DilC18 (3) dye were excited through skin and the emis-
sion signals were used to calculate tumour sizes. We
observed a correlation between tumour volumes (Figure
3C-G).
The proliferation status of cells within tumours was
analyzed after sacrifice by using different markers. For
Ki-67 (a proliferation marker from G2/M phase), more
than 60% of cells overexpressing GFP-aurC-WT and
GFP-aurC-CA were positive for Ki-67 but less than 2%
of the injected cells of GFP-alone were positive for Ki-
67 (Figure 3D). Feulgen staining of tumours induced by
GFP-aurC-WT and GFP-aurC-CA showed abnormal fig-
ures of mitosis such as abnormal prometaphase (92%),
abnormal metaphase (90%) (Figure 3F) lagging chromo-
somes (85%) and cytoplasmic bridges (80%) (Figure 3G).
No such types of abnormalities were observed in cells
overexpressing GFP-alone.
Immunostaining of phosphor-histone H3-serine-10
was used to evaluate the percentage of cells in M-phase.
More than 16% of cells overexpressing GFP-aurC-WT
or GFP-aurC-CA were histone H3 positive whereas less
than 2% of cells overexpressing GFP-alone were positive
for histone H3 (Figure 3E). Thus the histological
analysis of these tumours confirmed high proliferation
rate of both GFP-aurC-WT and GFP-aurC-CA and
chromosomal abnormalities.
Discussion
All the three members of Aurora kinase family have
been detected in human cancers when they are overex-
pressed [10-12]. In this study, whether or not aurora-C-
T191D mutant is constitutively active, was in question.
We compared the potential to induce cell growth in soft
agar and tumour of stable cell lines overexpressing GFP-
aurC-WT, GFP-aurC-T191D (GFP-aurC-CA expressing
the constitutively active GFP-tagged aurC) and GFP as a
control.
We showed in vitro kinase assays that the relative
activity of histone H3 phosphorylation by GFP-aurC-CA
was the same as that by GFP-aurC-WT (Figure 1G-I).
These results are in contrast to those previously
described [20]. This might be due to the reason that we
used mouse NIH3T3 cell line. The GFP-aurC-KD did
not phosphorylate Histone H3.
Abnormal expression of Aurora kinases causes abnor-
mal centrosomes amplification and multinucleation
[6,17,21]. Both Aurora-A and Aurora-B overexpression
phenotypes are aggravated in the absence of active p53
[6,22]. An elimination of the p53-dependent checkpoint
may be evoked [23] to explain centrosome amplification
and multinucleation induced by Aurora-C. Moreover,
overexpressed Aurora-C kinase behaves like a dominant
negative kinase for Aurora-B leading to cytokinesis
defect that could explain the multinucleation phenotype
observed in Aurora-C overexpressing cells [6]. We
demonstrated that the overexpression of only active
GFP-Aurora-C-CA or Aurora-C-WT induces centro-
some amplification and multinucleation (Figure 2).
Although all Aurora kinases are found overexpressed
in cancer cells, their direct implication in oncogenesis
varies. During interphase Aurora-C localizes to the cen-
trosomes just like Aurora-A, both of them demonstrat-
ing oncogenic potentials. Moreover, centrosome
amplification, a common feature of Aurora-A and Aur-
ora-C overexpression, is a frequent event in almost all
types of solid cancer [24-26]. Interestingly, the kinase
activity of Aurora-A is not essential for induction of
centrosome amplification, however, the oncogenic trans-
formation requires kinase activity. Aurora-B by itself
cannot induce transformation of cells but augments
Ras-mediated transformation [27,28]. Aurora-B and -C
have overlapping functions and compete each other for
their substrates and other chromosome passenger pro-
teins [11]. INCENP and Survivin have stronger affinity
for Aurora-B than for Aurora-C [11] but interestingly
Aurora-C can complement the functions of Aurora-B in
mitotic cells. Although it is likely that the oncogenic
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Page 6 of 9Figure 3 Soft agar assay, tumour formation and immunohistochemistry. (A) Foci of colonies of GFP-aurA, GFP-aurC-CA, GFP-aurC-WT stable
cell lines and very negligible number of very small colonies of GFP-alone in soft agar assay. (B) Histogram of the average number of colonies.
(C) Visualization of the tumours formed by injecting GFP-aurC-CA and GFP-aurC-WT stable cell lines, and the remaining injected cells of GFP-
alone on the day of sacrifice using Kodak image station 2000. (D) Rabbit monoclonal KI-67, a proliferation marker from late G1 to M-phase
staining (E) anti-phospho histone-H3 ser-10 (Millipore) and anti-HRP (Jackson) secondary antibodies and (F & G) Feulgen staining showing
prometaphase defects, metaphase defects, lagging chromosomes at anaphase, and cytokinesis defect.
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(Aurora-A like) rather to its mitotic function related to
its chromosome passenger behaviour (Aurora-B like)
this remains to be deciphered. Similarly we found that
the overexpression of Aurora-C induces tumour forma-
tion when injected into nude mice, but this needs kinase
activity (Figure 3).
It is demonstrated that through both in vitro and in
vivo transformations, overexpression of Aurora-C-CA
and Aurora-C-WT in somatic cells has an oncogenic
potential and have almost equal relative activity. Thus
GFP-aurC-CA is constitutively active kinase mutant, at
least in mouse NIH-3 T3 cells, and not hyperactive
mutant as has been described earlier in Hela cells and
in U2OS cells. Here we used human Aurora-C gene in
mouse NIH3T3 cells that needs further to be explored,
at least mouse Aurora-C gene in mouse cells.
Conclusion
On the basis of above stated results and analysis, we
thus concluded that at least in NIH-3 T3 cells, the
human Aurora C-T191D is constitutively active mutant,
and not hyperactive mutant.
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